Cargando…
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
Bortezomib is a proteasome inhibitor used for the treatment of relapsed/refractory multiple myeloma (MM). However, intrinsic and acquired resistance to bortezomib has already been observed in MM patients. In a previous report, we demonstrated that changes in the expression of mitochondrial genes lea...
Autores principales: | Song, In-Sung, Jeong, Yu Jeong, Jeong, Seung Hun, Heo, Hye Jin, Kim, Hyoung Kyu, Lee, Sung Ryul, Ko, Tae Hee, Youm, Jae Boum, Kim, Nari, Ko, Kyung Soo, Rhee, Byoung Doo, Han, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809360/ https://www.ncbi.nlm.nih.gov/pubmed/24158003 http://dx.doi.org/10.1038/emm.2013.104 |
Ejemplares similares
-
KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway
por: Song, In-Sung, et al.
Publicado: (2015) -
Mitochondrial pyruvate dehydrogenase phosphatase 1 regulates the early differentiation of cardiomyocytes from mouse embryonic stem cells
por: Heo, Hye Jin, et al.
Publicado: (2016) -
Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy
por: Song, In-Sung, et al.
Publicado: (2011) -
The direct modulatory activity of zinc toward ion channels
por: Noh, Sujin, et al.
Publicado: (2015) -
BH4 activates CaMKK2 and rescues the cardiomyopathic phenotype in rodent models of diabetes
por: Kim, Hyoung Kyu, et al.
Publicado: (2020)